{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T08:58:22Z","timestamp":1775725102807,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Umea University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metastasis-directed stereotactic body radiotherapy (MD-SBRT) has shown promise in retrospective and phase II studies for oligometastatic hormone-sensitive prostate cancer. However, prospective randomized phase III data\u2014particularly in newly diagnosed cases and in combination with androgen deprivation therapy and next-generation androgen receptor pathway inhibitors\u2014are limited. The METRO trial investigates the addition of MD-SBRT to standard of care in patients with prostate-specific membrane antigen (PSMA) PET\/CT-detected oligometastatic disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>METRO is a multicentre, double arm, open-label, phase III randomized trial comparing MD-SBRT plus standard of care versus standard of care alone in patients with one to three PSMA PET\/CT-detected distant metastases. The PSMA-RADS scale is used to support inclusion, and only patients with PSMA-RADS 4 or 5 lesions in bone or non-regional lymph nodes are eligible.<\/jats:p>\n                    <jats:p>Standard of care includes time-limited androgen deprivation therapy and\/or androgen receptor pathway inhibitor, as well as local radiotherapy to the prostate or prostate bed. Patients are stratified by disease type (synchronous or metachronous) and metastasis location (lymph node\/bone). The primary endpoint is biochemical progression-free survival; secondary endpoints include time to castration-resistant prostate cancer, adverse events, and health-related quality of life.<\/jats:p>\n                    <jats:p>The intervention is prescribed either 30\u00a0Gy in 3 fractions or 40\u00a0Gy in 5 fractions and delivered by stereotactic treatment principles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The METRO trial investigates the added value of combining MD-SBRT with time-limited intensified hormonal therapy in both synchronous and metachronous oligometastatic hormone-sensitive prostate cancer staged by PSMA\u2011PET\/CT. The use of the PSMA-RADS scale for inclusion ensures a standardized and reproducible approach for patient selection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov Identifier: NCT04983095.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-15906-6","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T13:34:00Z","timestamp":1774445640000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Metastasis-directed SBRT for oligometastatic hormone sensitive prostate cancer (METRO): protocol for a prospective randomised phase III trial, NCT04983095"],"prefix":"10.1186","volume":"26","author":[{"given":"Karin","family":"S\u00f6derkvist","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maira","family":"Zia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adalsteinn","family":"Gunnlaugsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Josefsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f8rg","family":"Aksness\u00e6ther","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunde","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilla","family":"Thellenberg-Karlsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Alm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Kudr\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Lundin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Moise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny Kahlmeter","family":"Brandell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon","family":"Kindblom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsten","family":"Bj\u00f6rnlinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrine","family":"Riklund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Westin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mattias","family":"Hedman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie","family":"Skorve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pernilla","family":"Wikstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Strandberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joakim","family":"Jonsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"issue":"5","key":"15906_CR1","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","volume":"36","author":"P Ost","year":"2018","unstructured":"Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol. 2018;36(5):446\u201353.","journal-title":"J Clin Oncol"},{"issue":"5","key":"15906_CR2","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","volume":"6","author":"R Phillips","year":"2020","unstructured":"Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES, et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer. JAMA Oncol. 2020;6(5):650\u20139.","journal-title":"JAMA Oncol"},{"issue":"5","key":"15906_CR3","doi-asserted-by":"publisher","first-page":"e344","DOI":"10.1016\/j.prro.2024.04.022","volume":"14","author":"AJ Conde-Moreno","year":"2024","unstructured":"Conde-Moreno AJ, L\u00f3pez-Campos F, Herv\u00e1s A, Morillo V, M\u00e9ndez A, Puertas MDM, et al. A phase II trial of stereotactic body radiation therapy and androgen deprivation for oligometastases in prostate cancer (SBRT-SG 05). Pract Radiat Oncol. 2024;14(5):e344\u201352.","journal-title":"Pract Radiat Oncol"},{"issue":"10231","key":"15906_CR4","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208\u201316.","journal-title":"Lancet"},{"issue":"2","key":"15906_CR5","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1097\/JU.0000000000001369","volume":"205","author":"F Crocerossa","year":"2021","unstructured":"Crocerossa F, Marchioni M, Novara G, Carbonara U, Ferro M, Russo GI, et al. Detection rate of prostate specific membrane antigen tracers for positron emission tomography\/computerized tomography in prostate cancer biochemical recurrence: a systematic review and network meta-analysis. J Urol. 2021;205(2):356\u201369.","journal-title":"J Urol"},{"issue":"4","key":"15906_CR6","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","volume":"77","author":"M Perera","year":"2020","unstructured":"Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, et al. <article-title update=\"added\">Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer\u2014updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol. 2020;77(4):403\u201317.","journal-title":"Eur Urol"},{"issue":"4","key":"15906_CR7","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","volume":"71","author":"P Cornford","year":"2017","unstructured":"Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: Treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71(4):630\u201342.","journal-title":"Eur Urol"},{"issue":"6","key":"15906_CR8","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1016\/j.acra.2024.12.027","volume":"32","author":"FA Mourato","year":"2025","unstructured":"Mourato FA, Schmitt LG, Mariussi M, Torri GB, Altmayer S, Mirshahvalad SA, et al. Prognostic value of response evaluation using PSMA PET\/CT in patients with metastatic prostate cancer (RECIP 1.0): a systematic review and meta-analysis. Acad Radiol. 2025;32(6):3421\u20138.","journal-title":"Acad Radiol"},{"issue":"4","key":"15906_CR9","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.eururo.2017.10.027","volume":"73","author":"SP Rowe","year":"2018","unstructured":"Rowe SP, Pienta KJ, Pomper MG, Gorin MA. PSMA-RADS version 1.0: a step towards standardizing the interpretation and reporting of PSMA-targeted PET imaging studies. Eur Urol. 2018;73(4):485\u20137.","journal-title":"Eur Urol"},{"issue":"5","key":"15906_CR10","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.eururo.2023.06.008","volume":"84","author":"RA Werner","year":"2023","unstructured":"Werner RA, Hartrampf PE, Fendler WP, Serfling SE, Derlin T, Higuchi T, et al. Prostate-specific membrane antigen reporting and data system version 2.0. Eur Urol. 2023;84(5):491\u2013502.","journal-title":"Eur Urol"},{"issue":"2","key":"15906_CR11","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.ijrobp.2021.09.004","volume":"112","author":"TK Nguyen","year":"2022","unstructured":"Nguyen TK, Chin L, Sahgal A, Dagan R, Eppinga W, Guckenberger M, et al. International multi-institutional patterns of contouring practice and clinical target volume recommendations for stereotactic body radiation therapy for non-spine bone metastases. Int J Radiat Oncol Biol Phys. 2022;112(2):351\u201360.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"15906_CR12","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.eururo.2018.10.011","volume":"75","author":"T Van den Broeck","year":"2019","unstructured":"Van den Broeck T, van den Bergh RCN, Arfi N, Gross T, Moris L, Briers E, et al. Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review. Eur Urol. 2019;75(6):967\u201387.","journal-title":"Eur Urol"},{"key":"15906_CR13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.radonc.2019.11.026","volume":"145","author":"EM Dunne","year":"2020","unstructured":"Dunne EM, Sahgal A, Lo SS, Bergman A, Kosztyla R, Dea N, et al. International consensus recommendations for target volume delineation specific to sacral metastases and spinal stereotactic body radiation therapy (SBRT). Radiother Oncol. 2020;145:21\u20139.","journal-title":"Radiother Oncol"},{"issue":"5","key":"15906_CR14","doi-asserted-by":"publisher","first-page":"e597","DOI":"10.1016\/j.ijrobp.2012.03.009","volume":"83","author":"BW Cox","year":"2012","unstructured":"Cox BW, Spratt DE, Lovelock M, Bilsky MH, Lis E, Ryu S, et al. International spine radiosurgery consortium consensus guidelines for target volume definition in spinal stereotactic radiosurgery. Int J Radiat Oncol Biol Phys. 2012;83(5):e597\u2013605.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10323","key":"15906_CR15","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","volume":"399","author":"G Attard","year":"2022","unstructured":"Attard G, Murphy L, Clarke NW, Cross W, Jones RJ, Parker CC, et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet. 2022;399(10323):447\u201360.","journal-title":"Lancet"},{"issue":"1","key":"15906_CR16","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13014-024-02559-7","volume":"19","author":"AE Persson","year":"2024","unstructured":"Persson AE, Hallqvist A, Bj\u00f8rn Larsen L, Rasmussen M, Scherman J, Nilsson P, et al. Stereotactic body radiotherapy as metastasis-directed therapy in oligometastatic prostate cancer: a systematic review and meta-analysis of randomized controlled trials. Radiat Oncol. 2024;19(1):173.","journal-title":"Radiat Oncol"},{"issue":"11","key":"15906_CR17","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/S1470-2045(10)70223-0","volume":"11","author":"M Bolla","year":"2010","unstructured":"Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol. 2010;11(11):1066\u201373.","journal-title":"Lancet Oncol"},{"issue":"12","key":"15906_CR18","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1016\/S1470-2045(19)30486-3","volume":"20","author":"C Carrie","year":"2019","unstructured":"Carrie C, Magn\u00e9 N, Burban-Provost P, Sargos P, Latorzeff I, Lagrange JL, et al. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. Lancet Oncol. 2019;20(12):1740\u20139.","journal-title":"Lancet Oncol"},{"issue":"4","key":"15906_CR19","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.eururo.2021.06.010","volume":"80","author":"S Supiot","year":"2021","unstructured":"Supiot S, Vaugier L, Pasquier D, Buthaud X, Magn\u00e9 N, Peiffert D, et al. OLIGOPELVIS GETUG P07, a Multicenter Phase II Trial of Combined High-dose Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Node Relapses in Prostate Cancer. Eur Urol. 2021;80(4):405\u201314.","journal-title":"Eur Urol"},{"issue":"10338","key":"15906_CR20","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1016\/S0140-6736(21)01790-6","volume":"399","author":"A Pollack","year":"2022","unstructured":"Pollack A, Karrison TG, Balogh AG, Gomella LG, Low DA, Bruner DW, et al. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology\/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. Lancet. 2022;399(10338):1886\u2013901.","journal-title":"Lancet"},{"issue":"6","key":"15906_CR21","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.eururo.2019.08.006","volume":"76","author":"AP Hoyle","year":"2019","unstructured":"Hoyle AP, Ali A, James ND, Cook A, Parker CC, de Bono JS, et al. Abiraterone in \u201chigh-\u201d and \u201clow-risk\u201d metastatic hormone-sensitive prostate cancer. Eur Urol. 2019;76(6):719\u201328.","journal-title":"Eur Urol"},{"key":"15906_CR22","doi-asserted-by":"crossref","unstructured":"Saad F, Vjaters E, Shore N, Olmos D, Xing N, Pereira de Santana Gomes AJ, et al. Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial. J Clin Oncol. 2024;42(36):4271\u201381.","DOI":"10.1200\/JCO-24-01798"},{"issue":"20","key":"15906_CR23","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1200\/JCO.20.03488","volume":"39","author":"KN Chi","year":"2021","unstructured":"Chi KN, Chowdhury S, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al. Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study. J Clin Oncol. 2021;39(20):2294\u2013303.","journal-title":"J Clin Oncol"},{"issue":"1","key":"15906_CR24","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.eururo.2019.02.003","volume":"76","author":"S Burdett","year":"2019","unstructured":"Burdett S, Boev\u00e9 LM, Ingleby FC, Fisher DJ, Rydzewska LH, Vale CL, et al. Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: a STOPCAP systematic review and meta-analysis. Eur Urol. 2019;76(1):115\u201324.","journal-title":"Eur Urol"},{"issue":"6","key":"15906_CR25","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S1470-2045(25)00197-4","volume":"26","author":"P Ost","year":"2025","unstructured":"Ost P, Siva S, Brabrand S, Dirix P, Liefhooghe N, Otte FX, et al. Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V-STORM): a phase 2, open-label, randomised controlled trial. Lancet Oncol. 2025;26(6):695\u2013706.","journal-title":"Lancet Oncol"},{"key":"15906_CR26","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","volume":"148","author":"Y Lievens","year":"2020","unstructured":"Lievens Y, Guckenberger M, Gomez D, Hoyer M, Iyengar P, Kindts I, et al. Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document. Radiother Oncol. 2020;148:157\u201366.","journal-title":"Radiother Oncol"},{"issue":"12","key":"15906_CR27","first-page":"djv261","volume":"107","author":"C Sweeney","year":"2015","unstructured":"Sweeney C, Nakabayashi M, Regan M, Xie W, Hayes J, Keating N, et al. The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP). J Natl Cancer Inst. 2015;107(12):djv261.","journal-title":"J Natl Cancer Inst."}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15906-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15906-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15906-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T08:04:32Z","timestamp":1775721872000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15906-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15906"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15906-6","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"21 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All subjects will receive written and oral information about the aims of the study,\u00a0possible hazards, and the mechanism of treatment allocation by their treating physiscian. They will be informed about the strict confidentiality of their patient data, but that their medical records may be reviewed for trial purposes by authorized individuals other than their treating physician. It will be emphasized that the participation is voluntary and that the patient is allowed to decline further participation whenever he wants. If the patient wishes to withdraw from the study, he will be offered the standard treatment at the clinic. A signed, informed consent must be obtained from the patient before study entry. In the cases were the patient declines to\u00a0participate\u00a0in the study the conventional treatment according to local practice should be offered. Applicable\u00a0details from this protocol and\u00a0all\u00a0accompanying material provided to the patient, such as written patient information used to obtain informed consent,\u00a0has been\u00a0submitted\u00a0by the investigator to the Swedish Ethical Review Authority. Approval from the authority\u00a0has been granted 2021\u201306-22\u00a0(ref.nr.\u00a02021\u201302766),\u00a0amended 2023\u201303-07\u00a0(ref.nr.\u00a02023\u201301224-02),\u00a02023\u201307-19 (ref.nr. 2023\u201304372-02),\u00a02024\u201306-05\u00a0(ref.nr.\u00a02024\u201302744-02)\u00a0and 2025\u201303-18 (ref.nr.\u00a02025\u201301461-02) and from the Regional Committee for Medical and Health Research Ethics, Mid-Norway (ref. no. 752599). Any significant changes to the protocol will be submitted for renewed ethical review.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Maira Zia is employed by Antaros Medical and declares no competing interests. All other authors declare no competing interests.The authors declare no competing intereests..","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"456"}}